To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
217 Current news from the ressort lawsrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Merck announced that the Japan Patent Office and the Intellectual Property Office of Singapore have each allowed the company’s patent application for the use of paired CRISPR nickases, bringing Merck’s number of patents to 22 worldwide. “Paired nickases represent a significant step in increasing ...
ECHA’s Committee for Socio-economic Analysis (SEAC) adopted its final opinion supporting the proposal by Denmark, Italy, Norway and ECHA to restrict the placing on the market of tattoo inks and permanent make-up. Substances within the scope of the restriction include carcinogenic, mutagenic and ...
Merck announced that the Canadian Patent Office has allowed Merck’s patent application directed to the use of paired CRISPR nickases in eukaryotic cells. The patent provides an important and more specific solution for scientists who need accurate methods when developing treatments for ...
Toxicity testing of microparticles and poorly soluble liquids in the water environment
A Task Force set up by the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) has provided new insights into scientific testing for the impact of undissolved particles in the aquatic environment. ECETOC launched the Task Force in response to increasing concerns among the ...
New agreement supports sharing, innovation and openness
A new easy-to-use legal tool that enables open exchange of biological materials is launched. The OpenMTA is a Material Transfer Agreement (MTA) designed to support openness, sharing and innovation in global biotechnology. Material Transfer Agreements (MTAs) provide the legal frameworks within ...
Recipharm has released its first serialised products to Europe from its facilities in Lisbon, Portugal and Stockholm, Sweden. In 2016 Recipharm committed to invest 40 million euros in preparing its facilities for the European Falsified Medicines Directive (EU FMD). The release of its first batch ...
On the occasion of the 10th European Antibiotic Awareness Day, the European Centre for Disease Prevention and Control (ECDC) is releasing its latest EU-wide data on antibiotic resistance, as well as its guidance on prevention and control of carbapenem-resistant Enterobacteriaceae (CRE). In 2016, ...
BVMed, Earlybird, High-Tech Gründerfonds and BIOCOM publish “MedTech Radar 9”
The EU Medical Device Regulation heralds a new era for the medical technology sector: in future, any company wishing to bring medical devices to market must face the requirements of this new regulatory framework. This implies a sizeable challenge for the many small and medium-sized enterprises in ...
Related patent application recently awarded in Australia
Merck announced the European Patent Office (EPO) has issued a “Notice of Intention to Grant” for Merck’s patent application covering the company’s CRISPR technology used in a genomic integration method for eukaryotic cells. The patent will provide Merck’s CRISPR genomic integration technology ...
Business continuity plan aims to preserve Agency’s ability to protect public and animal health
The European Medicines Agency (EMA) has developed and initiated a business continuity plan to deal with the uncertainty and workload implications linked to the United Kingdom’s (UK’s) withdrawal from the European Union (EU) and the Agency’s relocation. “Preparing for the move, managing the ...